EValuate Diagnostics utilizes circulating extracellular vesicles to purify and identify tumor biomarkers, enabling early and non-invasive cancer detection. This technology enhances diagnostic accuracy, facilitating timely disease intervention and improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for detecting diseases like cancer often rely on traditional imaging or tissue biopsies, which may not detect the disease at its earliest stages. This can lead to delayed diagnosis and treatment, potentially reducing the chances of successful outcomes. There is a need for non-invasive methods that can detect diseases earlier and more rapidly.
Solution
EValuate Diagnostics is developing a platform for the targeted capture and analysis of circulating extracellular vesicles (EVs) to enable earlier and non-invasive disease detection. By harnessing the biological richness of EVs, the company aims to identify tumor biomarkers in biofluids like blood, even before traditional methods can detect the disease. Their diagnostic assays are designed to monitor disease biomarkers, facilitating timely intervention and improving patient outcomes. The company's technology utilizes advances in EV isolation and analysis, combined with next-generation sequencing, to detect RNA signatures indicative of developing cancer.
Target Audience
The primary target audience includes healthcare providers and researchers focused on early disease detection, particularly in oncology, as well as individuals seeking proactive health monitoring solutions.
Features
- Targeted capture of circulating extracellular vesicles (EVs) from biofluids
- Identification of tumor-specific RNA signatures using next-generation sequencing
- Non-invasive liquid biopsy approach for early disease detection
- Diagnostic assays for monitoring disease biomarkers